Michael M. Matin
Chairman of the Board, CEO

Michael Matin is the founder of HDL Therapeutics and is the CEO and the Chair of its Board of Directors. Michael leads the company’s strategic and operational management and has steered the advancement of the HDL Therapeutics’ lead program into an FDA approved novel cardiovascular treatment. Michael has successfully raised multiple rounds of capital and has led HDL Therapeutics from a single indication device company into a biotechnology and device company with multiple programs in multiple indications.

Prior to founding HDL Therapeutics, Michael worked for over 20 years in commercial roles in the pharmaceuticals industry, leading blockbuster cardiovascular and Alzheimer’s disease product launches.

Michael received his B.S.F.S. from the School of Foreign Service at Georgetown University and his MBA from Columbia University.

H. Bryan Brewer, MD
Chief Scientific Officer

Bryan is a co-founder of HDL Therapeutics, and is the Chief Scientific Officer of the company. He leads the clinical development program of the company. Bryan was previously a member of the Board of the National Cholesterol Education Program, which established treatment guidelines for patients with hyperlipidemia in the United States, and has served on the editorial boards of several prestigious journals including Clinical Lipidology. Bryan’s research led to the elucidation of the first published sequences for the human plasma apolipoproteins, the initial determination of the metabolism of the plasma apolipoproteins in normal and hyperlipidemic individuals, as well as the identification of multiple gene defects leading to the genetic dyslipoproteinias. He has pioneered the use of transgenic mice and rabbits as well as recombinant adenovirus vectors to identify genes that modulate lipoprotein metabolism and the development of atherosclerosis. Bryan has published more than 450 original manuscripts and 75 reviews and book chapters on the subjects of genetic dyslipoprotenias, lipoprotein metabolism, and atherosclerosis.

Bryan is a recipient of the JD Lane Investigator Award from the US Public Health Service, the Heinrich Wieland Prize from the Federal Republic of Germany and the Public Health Service Commendation Award, Meritorious & Service, Distinguished Service Medals from the NIH, George Lyman Duff Memorial Award Lecture, and the Robert I. Levy Award.

Prior to co-founding HDL Therapeutics, Bryan was a Director, Washington Cardiovascular Associates, Senior Research Consultant, Lipoprotein and Atherosclerosis Research at the Cardiovascular Research Institute, a division of MedStar Research Institute, and Section Chief of the Molecular Disease Branch at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), a position he held for nearly 30 years.

Bryan received his medical degree from Stanford University School of Medicine. He completed his internship and residency in internal medicine at Massachusetts General Hospital.

D. J. Brignola
Chief Financial Officer

Nick joined our Team from Caris Life Sciences. Nick led the Finance and Revenue Cycle organizations at Caris since 2011. He built the Finance and Accounting operations team at Caris from the ground up, after the Company was spun off as a result of an acquisition. During his tenure at Caris, Nick led the Financial Planning, Accounting, Sales Operations and Treasury functions. During his last year at Caris, Nick was charged with helping the Company document processes and assess its internal control structure, as well as assisting the Company in its efforts to raise additional capital. Nick began his life science career at Schering-Plough as an auditor and held financial positions with increasing responsibilities in Manufacturing, Accounting, Finance, and Compliance. His last role at Schering-Plough was Finance Director in the Global Cardiovascular Franchise a $ 4 billion business at its peak. Nick was responsible for all aspects of planning and reporting for Schering’s portfolio of cardiovascular products in clinical development through commercialization. After Schering-Plough, Nick led the Commercial and Research Finance organizations at Shionogi, also serving as a Board Director and Treasurer for Shionogi Pharma. While at Shionogi, he helped re-build some of Shionogi’s accounting and governance processes, as well strengthened the Company’s Medicaid Drug Rebate program.

Nick received his B.S. in Business Logistics from The Pennsylvania State University and his MBA from Louisiana State University. Nick is also a Certified Internal Auditor and has earned professional certifications in Occupational Safety and Transportation and Logistics.

Michael McCann
Chief Commercial Officer

Mike is our chief commercial officer, responsible for the development and execution of the commercial launch strategy for the PDS-2TM System. He has over 25 years of biopharma commercial experience across sales, marketing, commercial operations, multiple product launches including major cardiovascular and rare disease products. 

Most recently he was Vice President Sales and Sales Operations at DBV Technologies. Prior to joining DBV Technologies he was Head, U.S. Sales & Marketing at Noden Pharma with responsibility for building the entire US commercial organization. Prior to Noden Pharma he was Head, U.S. Cardiovascular – Rare Diseases at Sanofi Genzyme. Prior to Sanofi Genzyme he was Vice President, Sales & Operations at Shionogi Inc. Prior to Shionogi he held various commercial leadership positions of increasing responsibility at Schering-Plough (now Merck) including Area Vice President, Sales and Senior Director, Cardiovascular Marketing U.S./Latin America. 

Mike received his B.B.A. in Marketing from Marshall University.

Timothy J. Perlman
VP, Systems Development & Clinical Operations

Tim is a member of HDL Therapeutics, Inc. leadership team, and has worked in the biomedical industry for over 20 years. He has a strong background in blood and plasma based new product/process development from concept through launch, and has led high performing teams, partners, and clinical sites to execute the development and implementation of cutting edge medical technologies. He is well versed in the U.S. and International regulatory requirements for medical devices.

Tim led the design and development of HDL Therapeutics’ Plasma Delipidation System, and oversaw the successful completion of the first-in-man clinical feasibility study. Over the course of his career, he has also been responsible for the development of a number of other blood/plasma processing therapies, including novel lipoprotein modification processes and systems, extracorporeal xenogeneic liver assist systems, and innovative pathogen inactivation processes intended to treat SIV and HIV. Tim has led programs in the diabetes management field, from the design and development of innovative xenogeneic implantable artificial pancreas devices, to next generation integrated blood glucose monitoring systems. Tim has published numerous abstracts and articles in such Journals as the Journal of the American College of Cardiology and the Journal of Lipid Research, and holds over a dozen issued patents in the field.

Tim received his Bachelor of Science in Mechanical Engineering with High Honors from Northeastern University in Boston, and conducted graduate studies in Biomedical Engineering at Worcester Polytechnic Institute in Worcester, Massachusetts.

Lori A. Carr, RAC, CQA, RABQSA
VP, Quality Management & Regulatory Affairs

Lori has 26 years of experience in the medical device field including Regulatory Compliance, Quality Assurance, Regulatory Affairs, Quality Systems, and Quality System Remediation. Lori is responsible to ensure full compliance of HDL Therapeutics’ manufacturing and established Quality Systems with Federal Regulations.

Lori began her FDA career in 1994 as an FDA Medical Device Registration Monitor and was a member of the FDA Foreign Inspection Cadre for Medical Devices. She conducted domestic and foreign Good Manufacturing Practice (GMP) and Quality System Regulation (QSR) inspections for premarket (including 510(k) and PMAs) and post-market inspections. Lori was an FDA Level II Certified Medical Device Investigator, which is an honor that is bestowed on FDA Investigators that have demonstrated special competence in conducting inspections. Lori has provided training at the FDA National Basic Medical Device School, which trains FDA Medical Device Investigators and industry groups on FDA inspection readiness.

Lori’s Professional Certifications include the Regulatory Affairs Certification (RAC/US) through the Regulatory Affairs Professionals Society (RAPS); Certified Quality Auditor (CQA) through American Society for Quality (ASQ); and RABQSA Principal Auditor (ISO 13485:2003) through Exemplar Global. Lori holds a BS degree in Chemistry from Xavier University in Cincinnati, Ohio.